IC
DGX icon

Inscription Capital’s Quest Diagnostics DGX Stock Holding History

Inscription Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
1,644
-157
-9% -$30.8K 0.03% 499
2026
Q1 		$353K Sell
1,801
-82
-4% -$15.9K 0.04% 447
2025
Q4 		$327K Buy
1,883
+664
+54% +$121K 0.03% 462
2025
Q3 		$232K Sell
1,219
-2,412
-66% -$428K 0.03% 534
2025
Q2 		$652K Sell
3,631
-1,464
-29% -$254K 0.09% 155
2025
Q1 		$678K Buy
+5,095
New +$837K 0.11% 141
2024
Q3 		$640K Sell
4,125
-820
-17% -$122K 0.1% 156
2024
Q2 		$677K Sell
4,945
-150
-3% -$20.5K 0.11% 139
2024
Q1 		$678K Sell
5,095
-430
-8% -$55.8K 0.11% 141
2023
Q4 		$762K Sell
5,525
-60
-1% -$7.89K 0.21% 85
2023
Q3 		$681K Hold
5,585
– – 0.22% 79
2023
Q2 		$785K Sell
5,585
-1,196
-18% -$165K 0.24% 74
2023
Q1 		$959K Sell
6,781
-300
-4% -$42.9K 0.25% 73
2022
Q4 		$1.11M Sell
7,081
-635
-8% -$91.3K 0.38% 62
2022
Q3 		$947K Sell
7,716
-75
-1% -$9.88K 0.27% 65
2022
Q2 		$1.04M Buy
7,791
+21
+0.3% +$2.86K 0.19% 91
2022
Q1 		$1.06M Buy
7,770
+90
+1% +$12.5K 0.3% 72
2021
Q4 		$1.33M Buy
7,680
+895
+13% +$136K 0.36% 65
2021
Q3 		$986K Buy
+6,785
New +$993K 0.31% 74
2021
Q2 		– Sell
-7,095
Closed -$911K – 329
2021
Q1 		$911K Sell
7,095
-735
-9% -$90.6K 0.31% 81
2020
Q4 		$933K Sell
7,830
-1,200
-13% -$146K 0.36% 69
2020
Q3 		$1.03M Sell
9,030
-750
-8% -$88.6K 0.46% 60
2020
Q2 		$1.11M Buy
9,780
+775
+9% +$82.2K 0.62% 45
2020
Q1 		$723K Sell
9,005
-180
-2% -$18.6K 0.48% 56
2019
Q4 		$981K Buy
9,185
+2,190
+31% +$228K 0.43% 62
2019
Q3 		$749K Buy
+6,995
New +$718K 0.41% 64

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Inscription Capital's DGX Position: Q2 2026 in Review

Inscription Capital reduced its Quest Diagnostics (DGX) stake by 8.7% in Q2 2026, selling an estimated $30.8K and leaving 1,644 shares worth $348K. The position accounts for 0.03% of the portfolio, ranked #499.

Inscription Capital first reported a position in DGX in Q3 2019 and has held it in 26 quarters since. The position peaked at $1.33M in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Inscription Capital held 1,644 shares of Quest Diagnostics worth $348K as of Q2 2026.
  • Inscription Capital sold 157 Quest Diagnostics shares in Q2 2026, an estimated $30.8K.
  • Quest Diagnostics made up 0.03% of Inscription Capital's portfolio in Q2 2026, its #499 holding.
  • Inscription Capital first reported a position in Quest Diagnostics in Q3 2019 and has held it in 26 quarters since.
  • Inscription Capital's Quest Diagnostics position peaked at $1.33M in Q4 2021.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.